Physicochemical Stability of the Rituximab Biosimilar ABP 798 in Intravenous Bags Following Preparation and Storage

Introduction: ABP 798 (rituximab-arrx, RIABNI ® ) is a biosimilar to rituximab available as a sterile, preservative-free solution (10 mg/mL) in a single-use vial for intravenous (IV) infusion. The purpose of this study was to assess the physicochemical stability of ABP 798 after dilution with 0.9% (w/v) saline or 5% (w/v) dextrose. Methods: Two experimental arms designated “preliminary hold” and “optimized storage condition” were assessed. For both arms, ABP 798 was diluted to 1 and 4 mg/mL with sterile 0.9% (w/v) saline or 5% (w/v) dextrose in IV bags. For the preliminary hold assessment, the IV bags were kept at 2°C to 8°C for up to 30 days, followed by storage at 30°C for 24 hours (h), and then infusion at ambient temperature. For the optimized storage condition assessment, the IV bags were kept at 2°C to 8°C for up to 30 days (saline-diluted) or up to 24 hours (dextrose-diluted), followed by storage at 30°C (saline-diluted) or 25°C (dextrose-diluted) for 24 hours and infusion at two different infusion rates. Samples collected at different time points were evaluated for various product quality attributes. Results: Saline-diluted ABP 798 was physicochemically stable after 30 days of storage at 2°C to 8°C followed by storage at 30°C for 24 hours, and then infusion, as determined by the absence of changes to quality attributes. Degradation was observed in dextrose-diluted ABP 798 after 30 days of storage at 2°C to 8°C followed by 24 hours storage at 30°C. Dextrose-diluted ABP 798 remained physicochemically stable after 24 hours storage at 2°C to 8°C followed by 24 hours at 25°C. Conclusions: These results indicate that ABP 798 remains chemically and physically stable when diluted in IV bags with 0.9% (w/v) saline stored at 2°C to 8°C for 30 days or 5% (w/v) dextrose stored at 2°C to 8°C for 1 day. Overall, these findings provide strong evidence supporting the chemical and physical stability of ABP 798 under the tested conditions. It is essential for the end-user to ensure the overall quality of the prepared admixture by strictly adhering to the product’s packaging insert instructions.

Authors

Institutions

Publication Details

Journal
Hospital Pharmacy
Published
2026-03-28
DOI
https://doi.org/10.1177/00185787261424835
Primary Topic
Biosimilars and Bioanalytical Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Physicochemical Stability of the Rituximab Biosimilar ABP 798 in Intravenous Bags Following Preparation and Storage

Jeremy Gastwirt, Monica Goss, Golnaz Kamalinia, David Lai et al.
Hospital Pharmacy
Biosimilars and Bioanalytical Methods
article

Physicochemical Stability of the Rituximab Biosimilar ABP 798 in Intravenous Bags Following Preparation and Storage

Jeremy Gastwirt, Monica Goss, Golnaz Kamalinia, David Lai, Jeff Brown
article en

Abstract

Introduction: ABP 798 (rituximab-arrx, RIABNI ® ) is a biosimilar to rituximab available as a sterile, preservative-free solution (10 mg/mL) in a single-use vial for intravenous (IV) infusion. The purpose of this study was to assess the physicochemical stability of ABP 798 after dilution with 0.9% (w/v) saline or 5% (w/v) dextrose. Methods: Two experimental arms designated “preliminary hold” and “optimized storage condition” were assessed. For both arms, ABP 798 was diluted to 1 and 4 mg/mL with sterile 0.9% (w/v) saline or 5% (w/v) dextrose in IV bags. For the preliminary hold assessment, the IV bags were kept at 2°C to 8°C for up to 30 days, followed by storage at 30°C for 24 hours (h), and then infusion at ambient temperature. For the optimized storage condition assessment, the IV bags were kept at 2°C to 8°C for up to 30 days (saline-diluted) or up to 24 hours (dextrose-diluted), followed by storage at 30°C (saline-diluted) or 25°C (dextrose-diluted) for 24 hours and infusion at two different infusion rates. Samples collected at different time points were evaluated for various product quality attributes. Results: Saline-diluted ABP 798 was physicochemically stable after 30 days of storage at 2°C to 8°C followed by storage at 30°C for 24 hours, and then infusion, as determined by the absence of changes to quality attributes. Degradation was observed in dextrose-diluted ABP 798 after 30 days of storage at 2°C to 8°C followed by 24 hours storage at 30°C. Dextrose-diluted ABP 798 remained physicochemically stable after 24 hours storage at 2°C to 8°C followed by 24 hours at 25°C. Conclusions: These results indicate that ABP 798 remains chemically and physically stable when diluted in IV bags with 0.9% (w/v) saline stored at 2°C to 8°C for 30 days or 5% (w/v) dextrose stored at 2°C to 8°C for 1 day. Overall, these findings provide strong evidence supporting the chemical and physical stability of ABP 798 under the tested conditions. It is essential for the end-user to ensure the overall quality of the prepared admixture by strictly adhering to the product’s packaging insert instructions.

Hospital Pharmacy
Amgen (United States) (US)
Openalex Percentile: Top 4%
Biosimilars and Bioanalytical Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.